共 50 条
- [31] Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 studyLANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (08): : 611 - 621Ueno, MakotoIkeda, MasafumiMorizane, ChigusaKobayashi, SatoshiOhno, IzumiKondo, ShunsukeOkano, NaohiroKimura, KeisukeAsada, SuguruNamba, YoshinobuOkusaka, TakujiFuruse, Junji
- [32] Preliminary results of ENCORE 601, a phase 1 b/2, open-label study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC)JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Johnson, Melissa LynneAdjei, Alex A.Ramalingam, Suresh S.Janne, Pasi A.Dominguez, GeorgeGabrilovich, DmitryDeleon, LauraHasapidis, Jeannette LynneDiede, Scott J.Ordentlich, PeterHellmann, Matthew David
- [33] Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II studyANNALS OF ONCOLOGY, 2013, 24 (07) : 1813 - 1821Slovin, S. F.Higano, C. S.Hamid, O.Tejwani, S.Harzstark, A.Alumkal, J. J.Scher, H. I.Chin, K.Gagnier, P.McHenry, M. B.Beer, T. M.
- [34] Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label StudyJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14) : 2651 - +de Braud, FilippoDooms, ChristopheHeist, Rebecca S.Lebbe, CelesteWermke, MartinGazzah, AnasSchadendorf, DirkRutkowski, PiotrWolf, JuergenAscierto, Paolo A.Gil-Bazo, IgnacioKato, ShumeiWolodarski, MariaMcKean, MeredithCouselo, Eva MunozSebastian, MartinSantoro, ArmandoCooke, VesselinaManganelli, LucaWan, KittyGaur, AnilKim, JaeyeonCaponigro, GiordanoCouillebault, Xuan-MaiEvans, HelenCampbell, Catarina D.Basu, SumitMoschetta, MicheleDaud, Adil
- [35] AN OPEN-LABEL, MULTICENTER, PHASE 1/2 CLINICAL TRIAL OF RP1, AN ENHANCED POTENCY ONCOLYTIC HSV, COMBINED WITH NIVOLUMAB: UPDATED RESULTS FROM THE SKIN CANCER COHORTSJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A257 - A257Middleton, MarkAroldi, FrancescaSacco, JosephMilhem, MohammedCurti, BrendanVanderWalde, AriBaum, ScottSamson, AdelPavlick, AnnaChesney, JasonNiu, JiaxinRhodes, TerenceBowles, TawnyaConry, RobertOlsson-Brown, AnnaLaux, Douglas EarlKaufman, HowardBommareddy, PraveenDeterding, AlexSamakoglu, SeldaCoffin, RobertHarrington, Kevin
- [36] Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma Updated Results From a Phase 1/2 Open-label StudyJAMA ONCOLOGY, 2017, 3 (09)Powles, ThomasO'Donnell, Peter H.Massard, ChristopheArkenau, Hendrik-TobiasFriedlander, TerenceW.Hoimes, Christopher J.Lee, Jae LyunOng, MichaelSridhar, Srikala S.Vogelzang, Nicholas J.Fishman, Mayer N.Zhang, JingsongSrinivas, SandyParikh, JigarAntal, JoyceJin, XiaopingGupta, Ashok K.Ben, YongHahn, Noah M.
- [37] Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 studyLANCET ONCOLOGY, 2021, 22 (12): : 1692 - 1704Tawbi, Hussein A.Forsyth, Peter A.Hodi, F. StephenAlgazi, Alain P.Hamid, OmidLao, Christopher D.Moschos, Stergios J.Atkins, Michael B.Lewis, KarlPostow, Michael A.Thomas, Reena P.Glaspy, JohnJang, SekwonKhushalani, Nikhil, IPavlick, Anna C.Ernstoff, Marc S.Reardon, David A.Kudchadkar, RaginiTarhini, AhmadChung, CarolineRitchings, CoreyDurani, PiyushAskelson, MargaritaPuzanov, IgorMargolin, Kim A.
- [38] Interim Results From the Phase 1B and Phase 2 TORREY Open-label Extension Study of Seralutinib in Pulmonary Arterial Hypertension (PAH)AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209Sitbon, O.Sahay, S.Subias, P. EscribanoZolty, R. L.Kingrey, J. F.Penn, B.Sobol, I.Sood, N.Benza, R. L.Channick, R. N.Chin, K. M.Frantz, R. P.Hemnes, A. R.Howard, L. S.Mclaughlin, V. V.Vachiery, J.Zamanian, R. T.Cravets, M.Roscigno, R. F.Mottola, D.Parsley, E.Aranda, R.Zisman, L. S.Ghofrani, H.
- [39] Preliminary results of a Phase 1b, open-label, multicenter study of selgantolimod (GS-9688) in special populations of patients with chronic hepatitis BJOURNAL OF HEPATOLOGY, 2023, 78 : S1159 - S1160Agarwal, KoshCheng, Pin-NanLiu, Chun-JenDuan, RanKolhatkar, NikitaMateo, RobertoDa, BenRichards, ChristopherSowah, LeonardFletcher, SimonMendez, PatriciaChen, Chi-YiChuang, Wan-LongHolden Hsu, Yao-Chun
- [40] Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation studyLANCET HAEMATOLOGY, 2015, 2 (12): : E516 - E527Richardson, Paul G.Jagannath, SundarMoreau, PhilippeJakubowiak, Andrzej J.Raab, Marc S.Facon, ThierryVij, RaviWhite, DarrellReece, Donna E.Benboubker, LotfiZonder, JeffreyTsao, L. ClaireAnderson, Kenneth C.Bleickardt, EricSinghal, Anil K.Lonial, Sagar